Io Biotech Is A Clinical Stage Biopharmaceutical Company Based In Copenhagendenmarkwith An Office In New Yorkthe Company Specializes In Developing Immune Modulating Cancer Vaccines That Target Both Tumor Cells And Immune Suppressive Cells Within The Tumor Microenvironmenttheir Focus Is On Creating Off The Shelf Therapeutic Vaccines To Enhance Treatment Responses For Cancer Patients The Proprietary T Winaplatform Allows Io Biotech To Develop Dual Action Vaccines That Activate T Cells To Attack Tumor Cells While Countering Immune Suppressiontheir Lead Productcylembioa Io102 Io103 Is Currently In Phase 3 Clinical Trials For First Line Metastatic Melanoma And Has Received Breakthrough Therapy Designation From The Fda In Combination With Merckae S Keytrudaa Pembrolizumab The Company Is Also Advancing Additional Preclinical Candidatesaiming To Streamline Treatment Deployment And Establish Itself As A Leader In Immune Modulatory Cancer Vaccinesrecognized As One Of Fast Companyae S Worldae S Most Innovative Companies In 2025Io Biotech Is Committed To Improving Cancer Treatment Outcomes By Redefining The Tumor Microenvironment And Providing Durable Responses Through Its Innovative Vaccines
No conferences found for this company.
| Company Name | Io Biotech Aps |
| Country |
Denmark
|
| Address | N/A |
| Telephone | N/A |
| N/A |
